Close Menu

thalassemia

A CRISPR Go

US companies have begun recruiting for a CRISPR-based gene-editing trial to treat β-thalassemia, Stat News reports.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

The researchers reported correcting beta thalassemia in a mouse model via a gene editing method delivered by an intravenous injection.

The test uses multicolor high-resolution melt analysis to detect mutations that lead to a potentially fatal blood disorder particularly common in Asian populations.

The center, based in China, will focus on developing products targeting genetic conditions common in Asian populations. 

The group is testing its 42-gene panel on 1,100 individuals, and says it could be better at identifying population-specific variants than current blood typing methods. 

By Adam Bonislawski
Scientists at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust have launched SpotOn Clinical Diagnostics, a firm specializing in mass spec-based diagnosis of hemoglobin disorders.

Scientists from China's Xiamen University and a startup company called Xiamen Zeesan Biotech have submitted the test to Chinese regulatory officials for approval as a widespread prenatal diagnostic and screening tool for β-thalassemia.

Obama Ends hESC Research Restrictions, Connecticut Innovations, Helix Therapeutics, Canadian Forest Nanoproducts Network, Québec Consortium for Drug Discovery, Wisconsin Opportunity Grants, Wisconsin Emerging Industries Skills Partnership, Qatar Science & Technology Park

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.